Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer

BJU International

Volumn 100, Issue 4, 2007, Pages 786-793

  Rinnab, Ludwig ^a   Mottaghy, Felix M ^a,c   Blumstein, Norbert M ^a   Reske, Sven N ^a   Hautmann, Richard E ^a   Hohl, Kathrin ^a   Möller, Peter ^a   Wiegel, Thomas ^a   Kuefer, Rainer ^a   Gschwend, Juergen E ^b  

^a UNIVERSITY OF ULM   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

11C choline PET; Follow up; Prostate cancer; PSA; Re staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; CHOLINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; BLOOD; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION; FOLLOW UP; METHODOLOGY; MIDDLE AGED; PROGNOSIS; PROSTATE TUMOR; SCINTISCANNING; STANDARD; TUMOR RECURRENCE;

AGED; CHOLINE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 34548413330     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07083.x     Document Type: Article

References (34)

1. Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 1993 41 : 113 20
2. Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004 7 : 211 6
3. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 1993 150 : 1856 9
4. Boccon-Gibod L, Djavan WB, Hammerer P et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004 58 : 382 90
5. Guedea F, Aguilo F, Polo A et al. Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer. Radiother Oncol 2006 80 : 57 61
6. Wilkinson S, Chodak G. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol 2004 172 : 133 6
7. Scattoni V, Roscigno M, Raber M et al. Multiple vesico-urethral biopsies following radical prostatectomy. the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 2003 44 : 407 14
8. Cher ML, Bianco FJ Jr., Lam JS et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998 160 : 1387 91
9. Sella T, Schwartz LH, Swindle PW et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004 231 : 379 85
10. Okotie OT, Aronson WJ, Wieder JA et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004 171 : 2260 4
11. Wachter S, Tomek S, Kurtaran A et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006 24 : 2513 9
12. Picchio M, Messa C, Landoni C et al. Value of 11C choline-positron emission tomography for restaging prostate cancer: a comparison with 18F fluorodeoxyglucose-positron emission tomography. J Urol 2003 169 : 1337 40
13. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003 44 : 32 8
14. Reske SN, Blumstein NM, Glatting G. [PET and PET/CT in relapsing prostate carcinoma.]. Urologe A 2006 45 : 1240 50
15. Zeisel SH. Dietary choline: biochemistry, physiology, and pharmacology. Annu Rev Nutr 1981 1 : 95 121
16. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002 42 : 18 23
17. Kotzerke J, Prang J, Neumaier B et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000 27 : 1415 9
18. Yeh SD, Imbriaco M, Larson SM et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996 23 : 693 7
19. Schoder H, Herrmann K, Gonen M et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005 11 : 4761 9
20. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001 57 : 108 11
21. Heinisch M, Dirisamer A, Loidl W et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol Imaging Biol 2006 8 : 43 8
22. Fichtner J. [PSA recurrence following radical prostatectomy and radiotherapy.]. Urologe A 2006 45 : 1255 9
23. Roach M 3rd, Hanks G, Thames H et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer. recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006 65 : 965 74
24. Wilson AA, Garcia A, Jin L, Houle S. Radiotracer synthesis from [(11)C]-iodomethane: a remarkably simple captive solvent method. Nucl Med Biol 2000 27 : 529 32
25. Farsad M, Schiavina R, Castellucci P et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005 46 : 1642 9
26. Hricak H, Dooms GC, Jeffrey RB et al. Prostatic carcinoma. staging by clinical assessment, CT, and MR imaging. Radiology 1987 162 : 331 6
27. Horiguchi A, Nakashima J, Horiguchi Y et al. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Prostate 2003 56 : 23 9
28. Cornud F, Oyen R. [Role of imaging in the diagnosis and staging of prostatic adenocarcinomas]. J Radiol 2002 83 : 863 80
29. Huzjan R, Sala E, Hricak H. Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer. Nat Clin Pract Urol 2005 2 : 434 42
30. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999 36 : 31 5
31. Coleman R, DeGrado T, Wang S et al. Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000 3 : 147
32. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001 61 : 3599 603
33. Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T. 11C-choline positron emission tomography in prostate cancer. primary staging and recurrent site staging. Urol Int 2005 74 : 214 20
34. Stephenson AJ, Kattan MW. Nomograms for prostate cancer. BJU Int 2006 98 : 39 46